VC-Backed Flex Pharma Stumbles After Pricing Upsized IPO
Venture capital-backed leg spasm treatment developer Flex Pharma Inc. drew $86.4 million in its initial public offering after pricing above its range, but struggled in its first day of trading on...To view the full article, register now.
Already a subscriber? Click here to view full article